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ABSTRACT
Purpose: To assess the importance of sentinel lymph node biopsy in patients with cutaneous melanoma. Methods: Ninety 
consecutive non-randomized patients with stages I and II melanoma who underwent sentinel lymph node biopsy were fol-
lowed up prospectively for six years. Results: Patients were followed up for a mean period of 30 months. Their mean age 
was 53.3 years, ranging from 12 to 83 years. Thirty patients were male (37.5%) and 50, female (62.5%). Sentinel lymph 
node was positive in 32.5% and negative in 67.5%. It was found that the thicker the tumor, the greater the incidence of 
positive sentinel lymph nodes. In the group of patients with positive sentinel lymph nodes, recurrence occurred in 43.5%, 
but in those with negative sentinel lymph nodes, in only 7%, what points out to the association of tumor recurrence and 
positive sentinel lymph nodes. There were no major postoperative complications. Conclusion: Sentinel lymph node bi-
opsy was demonstrated to be a safe method for selecting patients who need therapeutic lymphadenectomy.
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RESUMO
Objetivo: Avaliar a importância da biópsia do linfonodo sentinela em pacientes com melanoma cutâneo Métodos: No-
venta pacientes com estadiamento I e II foram acompanhados prospectivamente no período de seis anos, de forma consec-
utiva e não randomizada e submetidos a biópsia do linfonodo sentinela. Resultados: Os pacientes foram acompanhados 
durante tempo médio de 30 meses. A média de idade dos pacientes foi de 53,3 anos, variando de 12 a 83. Quanto ao sexo, 
foram avaliados 30 pacientes do sexo masculino (37,5%) e 50 do sexo feminino (62,5%).32,5% dos pacientes apresenta-
ram linfonodo sentinela positivo e 67,5% linfonodo sentinela negativos. Comparando-se a espessura tumoral com a posi-
tividade	do	LS,	verificou-se	que	quanto	maior	a	espessura,	maior	a	incidência	de	positividade	do	linfonodo	sentinela.	No	
grupo	de	pacientes	com	LS	positivo	a	recorrência	surgiu	em	43,5%	dos	casos,	mostrando	a	relação	entre	a	recorrência	e	a	
positividade	do	LS.	Não	houve	complicações	no	pós-operatório.Conclusão: A biópsia do linfonodo sentinela mostrou-se 
um	método	seguro	para	selecionar	os	pacientes	que	necessitam	de	linfadenectomia	terapêutica.
Descritores: Melanoma. Linfonodos. Vasos Linfáticos. Diagnóstico.
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Introduction
Lymph	nodes	are	the	first	site	of	cutaneous	melanoma	
dissemination1.	Dissemination	is	sequentially	ordained	and	
melanoma progresses according to a pattern in most cases2. 
A	sentinel	lymph	node	(SL)	is	the	first	lymph	node	to	where	
the primary tumor drains3.	The	biopsy	technique	was	first	
described	 by	Morton,	who	 confirmed	 the	 hypothesis,	 by	
means of clinical experience, that the sentinel lymph node 
histopathology mirrors what is occurring in the remaining 
lymph nodes of the group assessed4. Sentinel lymph node 
biopsy for patients with localized cutaneous melanoma, 
that is, with no clinical evidence of locoregional or distant 
metastases,	 is	 also	 confined	 for	 patients	 whose	 primary	
lesion suggests the risk of lymph node metastases, such 
as Breslow thicker than 1.0 mm or despite thinner than 
1.0mm, displays other histopathological risk features, such 
as: Clark IV or V and ulceration5. Other risk factors, such 
as regression, high mitotic index (more than 6 mitoses/
mm³), vertical growth phase and lymphatic invasion 
are controversial6. This procedure has been included in 
cutaneous melanoma staging since 2002, after the AJCC/
UICC consensus7. In the same year, in Brazil, after the 
meeting of the Brazilian Melanoma Group Consensus, 
sentinel lymph node biopsy was indicated in cases with 
Breslow	 thickness	 equal	 to	 or	 greater	 than	 0.76	 mm8. 
Sentinel	lymph	node	biopsy	results	define	which	patients	
are the proper candidates for complete lymphadenectomy, 
sparing from it the individuals with unaffected sentinel 
lymph nodes9. It encompasses three fundamental steps: 
1. preoperative lymphocintigraph, performed by a nuclear 
medicine physician.
2. sentinel lymph node biopsy itself, utilizing vital stain 
lymphatic mapping and intraoperative gamma detection. 
This is done by a surgeon trained in the procedure. 
3. histopathological examination of the sentinel lymph 
node,	with	appropriate	techniques,	by	a	pathologist.
The lymphocintigraph localizes the regional drainning 
lymph nodes and allows localizing the sentinel lymph node 
projection under the skin. It is essential for accomplishing 
good results with the procedure. Patent blue lymphatic 
mapping simulates the lymphatic pathway the tumor 
cell could move between the primary skin lesion and the 
corresponding regional lymph nodes, staining the sentinel 
lymph node. Intraoperative gamma detection enables easier 
and less aggressive dissecting of the sentinel lymph node10. 
Breslow thickness and the presence of ulcerations in the 
primary lesion are the main independent indicators of the 
presence of sentinel lymph node metastases1.	The	finding	of	
micrometastases in the sentinel lymph node is considered 
the most important prognostic factor for melanoma 
recurrence5. Sentinel lymph node biopsy is a reproducible 
method for regional microstaging of melanoma in patients 
with clinically undetectable lymph node metastases9.
Epidemiologic studies reveal differences among 
melanoma case reports regarding type and lesion thickness. 
In Brazil, several public university hospitals report a higher 
incidence of thick and of acral lentiginous melanomas 
than what is reported from countries with predominantly 
Caucasian population. With the aim of assessing the 
method in a general university hospital, sentinel lymph 
node biopsies were performed as from 1999, in melanoma 
patients with Breslow thickness greater than 1.0 mm (and as 
from 2002, greater than 0.76 mm), who were prospectively 
followed up and the results were compared to those of the 
international literature. 
Methods
The study group was composed of 90 patients who 
underwent sentinel lymph node biopsy from 1999 to 2005, 
as previously approved by the Ethics Committee of the 
Institution. The patients signed informed consent forms. 
Patient selection was consecutive and non-randomized. 
They were prospectively followed up. Biopsy of the 
primary lesion was initially performed for diagnostic 
confirmation	 and	 assessment	 of	 Breslow	 thickness.	 All	
patients	with	tumor	thickness	equal	to	or	greater	than	1.0	
mm and with no clinical signs of lymph node metastases 
were included in the study.
Procedures
Preoperative lymphocintigraph was performed on 
the day prior to surgery, with 250 micro-Curies of the 
radioisotope (technetium) injected in the dermis, in the 
four cardinal points respective to the lesion or in the scar 
when a previous biopsy had been done, at a total dose of 
1000 micro-Curies. Images were obtained using the SPX 
4, Elscint scintillation camera. Patent blue (1 to 2 ml) 
was injected in the same cardinal points in the dermis on 
the benning of the surgery. A gamma detector was used 
intraoperatively, what helps to identify the lymph node 
and reduces the error margin. The sentinel lymph node 
was examined at pathology with hematoxillin-eosin 
stain and immunohistochemistry for HMB 45 and S-100 
protein, markers of melanoma, as an attempt to identify 
micrometastases.
Follow-up
All data were recorded in the protocol forms as well 
as in the patients’ hospital charts, for the entire follow-up 
time. All participants attended the skin tumors outpatient 
clinic of the Plastic Surgery Division every three months 
in	the	initial	three	years	and	every	six	months	up	to	five-
postoperative years.
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Analysis
The following data were assessed: age, sex, information 
on the primary tumor (localization, histopathological type, 
ulceration, Breslow and Clark), and histopathological 
diagnosis of SL, time of follow-up, recurrence and current 
patient status. Breslow thickness was categorized in four 
groups: A (0 to 1mm), B (1.01 to 2.0mm), C (2.01 to 4.0 
mm) and D (>4.0mm).
Results
Of the 90 patients studied, ten were excluded: 
in two, the sentinel lymph node was not found; in 
two, lymphadenectomy was done due to macroscopic 
involvement of the SL; four were lost to follow-up and 
two patients had in situ melanoma, which did not meet the 
study criteria. The mean follow-up time was 30 months. 
Patients lost to follow-up and with recurrences were 
uniformly distributed in the study period, as seen in the 
Kaplan-Meier estimator (Figure 1). The patients’ mean age 
was 53.3 years, ranging from 12 to 83 years. Thirty patients 
were male (37.5%) and 50, female (62.5%). Among the 80 
patients studied, in 26 (32.5%) the sentinel lymph node 
was positive and in 54 (67.5%), negative (Table 1). In the 
group of patients with positive SL, tumor thickness was 
between 0 –1.0 mm in three, between 1.01 – 2.0 mm in 
FIGURE 1 - Kaplan-Meier estimator for the survival curve
four, between 2.01 – 4.0 mm in seven and greater than 4.0 
mm in eleven. In the group of patients with negative SL, on 
the other hand, Breslow 0 – 1 mm was found in nine; 1.01 
– 2 mm, in 25; 2.01 – 3.0 mm, in 13 and greater than 4.0 
mm, in seven. Of the patients with positive SL, 45.9% had 
Breslow greater than 4.0 mm, while of those with negative 
SL	only	13.0%	fitted	 this	category.	Tumor	 thickness	was	
significantly	 different	 between	 the	 groups	 with	 positive	
and	negative	SL,	what	confirms	such	association	(p=0.008)	
(Table 1). The mean tumor thickness was 3.11 mm, and 
48.1% of them were thicker than 2.0 mm. Ulceration 
occurred in 29 patients (37.2%). All patients with Breslow 
thickness	equal	 to	or	grater	 than	0.76	mm	were	 included	
Variable	 	 Frequency	of	positive	(%)	 Frequency	of	negative	(%)	 p
Breslow 0,76 - 1.0 mm 3 (25) 9 (75)
 1.01 - 2.0 mm 4 (13.8) 25 (86.2) 0.008
 2.01 - 4.0 mm  7 (35)  13 (65)
 > 4.0 mm  11 (61.1)  7 (38.9)
 Not reported  1 (100)  0 (0)
Age  < 51 years  13 (39,4)  20 (60,6)  0.335
	 >=	51	years		 13	(27,7)		 34	(72,3)
Ulceration  Yes  11 (37.9)  18 (62.1)  0.456
 No  14 (28.6)  35 (71.4)
 Not reported  1 (50)  1 (50)
Tumor site  Head and neck  0 (0)  3 (100)
 Trunk  6 (20)  24 (80)  0.067
 Limbs  20 (42.55)  27 (57.45)
Recurrence  Yes  10 (58.8)  7 (41.2)  0.007
 No  13 (22.4)  45 (77.6)
 Not reported  3 (60)  2 (40)
Type		 Superficial	dissemination		 5	(16.1)		 26	(83.9)
 Nodular  10 (37)  17 (63)
 Acral  10 (71.4)  4 (28.6)  0.001
 Lentigo  1 (100)  0 (0)
	 Not	classified		 0	(0)		 7	(100)
Total   26 (32.5)  54 (67.5)  80 (100)
TABLE 1 – Distribution of positivity variables
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in the study, complying with the recommendations of the 
Brazilian Consensus on Sentinel Lymph Node, published 
by the Brazilian Melanoma Group, in 20038.  Histological 
type distribution was as follows: in the group with positive 
SL,	five	were	superficial	spreading,	ten,	nodular,	ten,	acral	
lentiginous and one, malignant lentigo. And in the group 
with	negative	SL,	26	were	superficial	spreading,	17,	nodular	
and four, acral lentiginous. Of the group of patients with 
negative SL, disease recurrence occurred in only 13.5% 
while in the one with positive SL, in 43.5%, what points 
to the association of tumor recurrence and positive SL 
(p=0.007)	(Table	1).		Of	the	patients	with	positive	SL,	in	
five	(21.7%)	the	disease	progressed	to	death;	this	was	found	
in four (7.7%) of the ones with negative SL. There was 
no	statistically	significant	association	of	tumor	recurrence	
and	 deaths	 (p=0.122)	 (Figure	 2).	 No	 local	 or	 systemic	
adverse reactions were observed after the injection of the 
radioisotope or of the vital stain. There was no dehiscence, 
infection or seroma at the sentinel lymph node biopsy site. 
By analyzing the patients of our service, it becomes evident 
that they present poor prognostic indicators, especially the 
thick Breslow measurement. However, of the 80 patients, 
55 had negative sentinel lymph nodes.
Discussion
Sentinel lymph node biopsy was developed by Morton, 
in 1992, as a minimally invasive surgical alternative for 
identifying occult micrometastases in patients who could 
benefit	from	total	lymphadenectomy2. Lymphatic mapping 
shows the anatomical pathway metastatic cell path from 
the	 primary	 tumor	 and	 identifies	 the	 lymph	 node	 to	 be	
meticulously	examined.	The	sentinel	lymph	node	is	the	first	
site of regional metastases; if the SL contains metastases, 
other lymph nodes of the same lymphatic drainage bed may 
also contain malignant cells.  Sentinel lymph node biopsy 
was added as part of the new melanoma AJCC (American 
Joint Committee of Cancer) staging system, in 20027. 
The presence of micro metastases in the regional lymph 
node is the most important prognostic factor in early stage 
FIGURE 2 - Recurrence pattern versus current patient status
cutaneous melanoma. Elective lymphadenectomy should 
improve survival of such patients, as micrometastases are 
found in 20% of them. However, it was abandoned after 
sentinel lymph node biopsy was introduced, because of 
complications due to the procedure, like lymphedema, 
and to the fact that survival was not improved by it 11,12,13.  
The intraoperative SL localization is indicated for patients 
with	 melanomas	 equal	 to	 or	 greater	 than	 1.0	 mm	 thick	
and no clinical evidence of lymph node metastases11. 
Approximately 20% of patients with melanoma with 
Breslow thickness between 1.0 and 4.0 mm show 
metastases in the sentinel lymph node, increasing to 34% 
in those with thickness greater than 4.0 mm and dropping 
to 4.7% in individuals with tumor thickness below 1.0 
mm associated with ulcerated lesion or Clark IV5.  Morton 
demonstrated that tumor thickness may be used as an 
indicator of expected lymph node metastases and that 
the sentinel lymph node biopsy  may accurately detect 
micrometastases of tumors thicker than 2.0 mm. However, 
in the case of thinner melanomas, the incidence may be 
underestimated12, 13. In the present study, 13.5% of patients 
with negative SL had tumor recurrence.  There is a direct 
relation between the presence of lymph node metastases and 
thickness of the primary tumor12,13,14,15. Similar results were 
found in the present study, in which nearly half the patients 
with affected SL had Breslow thickness above 4.0 mm. It 
was also seen that most lesions in the group with positive 
SL were of the clinical types nodular or acral lentiginous, 
that is, lesions in the phase of vertical growth, and thus 
with greater thickness6.  In patients with metastasis-free 
SL,	the	predominant	lesion	type	observed	was	superficial	
spreading, in which the initial growth phase is radial 
with no rapid invasion of the deepest skin layers6. In this 
group, perhaps due to racial admixture, the incidence of 
acral melanoma found was higher than that reported in the 
literature.  There were no intraoperative or postoperative 
complications, in agreement with the literature stating 
that SL biopsy is a low morbidity procedure, important 
for	determining	which	patients	will	benefit	from	complete	
lymphadnectomy10,12,13.  Until recently, SL biopsy was only 
considered as a staging gold-standard because there were 
no data proving it would increase patient survival. After the 
report by Morton et al.13, it became evident that survival of 
the group of patients with intermediate thickness tumors 
and positive SL biopsy might be increased by selective 
lymphadenectomy. Of the 80 patients studied, 49 had 
lesions of intermediate thickness, 11 of whom had positive 
SL. These patients were granted with the possibility of 
extended survival by selective lymphadenectomy.
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